- Home
- CSTL vs WRLD Comparison
CSTL vs WRLD Comparison
Compare CSTL & WRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- WRLD
- Stock Information
- Founded
- CSTL 2007
- WRLD 1962
- Country
- CSTL United States
- WRLD United States
- Employees
- CSTL N/A
- WRLD N/A
- Industry
- CSTL Medical Specialities
- WRLD Finance: Consumer Services
- Sector
- CSTL Health Care
- WRLD Finance
- Exchange
- CSTL Nasdaq
- WRLD Nasdaq
- Market Cap
- CSTL 661.7M
- WRLD 683.3M
- IPO Year
- CSTL 2019
- WRLD 1991
- Fundamental
- Price
- CSTL $33.85
- WRLD $131.71
- Analyst Decision
- CSTL Strong Buy
- WRLD
- Analyst Count
- CSTL 6
- WRLD 0
- Target Price
- CSTL $38.67
- WRLD N/A
- AVG Volume (30 Days)
- CSTL 391.5K
- WRLD 68.7K
- Earning Date
- CSTL 11-03-2025
- WRLD 10-23-2025
- Dividend Yield
- CSTL N/A
- WRLD N/A
- EPS Growth
- CSTL N/A
- WRLD N/A
- EPS
- CSTL N/A
- WRLD 10.75
- Revenue
- CSTL $343,530,000.00
- WRLD $570,763,378.00
- Revenue This Year
- CSTL N/A
- WRLD N/A
- Revenue Next Year
- CSTL N/A
- WRLD $3.55
- P/E Ratio
- CSTL N/A
- WRLD $12.49
- Revenue Growth
- CSTL 10.15
- WRLD 2.33
- 52 Week Low
- CSTL $14.59
- WRLD $104.99
- 52 Week High
- CSTL $35.84
- WRLD $185.48
- Technical
- Relative Strength Index (RSI)
- CSTL 85.44
- WRLD 32.78
- Support Level
- CSTL $23.31
- WRLD $129.24
- Resistance Level
- CSTL $34.36
- WRLD $136.58
- Average True Range (ATR)
- CSTL 1.46
- WRLD 7.43
- MACD
- CSTL 1.10
- WRLD -2.19
- Stochastic Oscillator
- CSTL 95.87
- WRLD 12.19
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.